Srinivas Muvvala, MD, MPH
Associate Professor of PsychiatryCards
Appointments
Additional Titles
Associate Program Director, Addiction Psychiatry Residency at Yale
Medical Director of the Substance use & Addiction Treatment Unit (SATU), Department of Psychiatry, Yale School of Medicine
Contact Info
Appointments
Additional Titles
Associate Program Director, Addiction Psychiatry Residency at Yale
Medical Director of the Substance use & Addiction Treatment Unit (SATU), Department of Psychiatry, Yale School of Medicine
Contact Info
Appointments
Additional Titles
Associate Program Director, Addiction Psychiatry Residency at Yale
Medical Director of the Substance use & Addiction Treatment Unit (SATU), Department of Psychiatry, Yale School of Medicine
Contact Info
About
Titles
Associate Professor of Psychiatry
Associate Program Director, Addiction Psychiatry Residency at Yale; Medical Director of the Substance use & Addiction Treatment Unit (SATU), Department of Psychiatry, Yale School of Medicine
Biography
Dr. Muvvala is an Associate Professor of Psychiatry and Associate Program Director for the Addiction Psychiatry Residency at the Yale School of Medicine. He is the Medical Director of the Substance use & Addiction Treatment Unit (SATU) at the Connecticut Mental Health Center. His research and clinical interests are in investigating and disseminating optimal therapies for the treatment of opioid, tobacco and alcohol use disorders and in providing comprehensive treatment for individuals with co-occuring addiction and psychiatric disorders.
Appointments
Psychiatry
Associate Professor on TermPrimary
Other Departments & Organizations
Education & Training
- Fellowship in Addiction Psychiatry
- Yale University School of Medicine (2010)
- Residency in General Psychiatry
- Drexel University College of Medicine (2009)
- MPH
- West Virginia University (2005)
- MD
- Andhra Medical College, NTR University of Health Sciences (2002)
Board Certifications
Addiction Psychiatry
- Certification Organization
- AB of Psychiatry & Neurology
- Original Certification Date
- 2012
Psychiatry
- Certification Organization
- AB of Psychiatry & Neurology
- Latest Certification Date
- 2020
- Original Certification Date
- 2010
Research
Research at a Glance
Yale Co-Authors
Publications Timeline
Kenneth Morford, MD, FASAM
Lisa Fucito, PhD
Ariadna Forray, MD
Geliang Gan, MPH, PhD
James Dziura, MPH, PhD
Oluwole Jegede, MD, MPH
Publications
2024
Placental cytochrome P450 methylomes in infants exposed to prenatal opioids: exploring the effects of neonatal opioid withdrawal syndrome on health horizons
Radhakrishna U, Sadhasivam S, Radhakrishnan R, Forray A, Muvvala S, Metpally R, Patel S, Rawal R, Vishweswaraiah S, Bahado-Singh R, Nath S. Placental cytochrome P450 methylomes in infants exposed to prenatal opioids: exploring the effects of neonatal opioid withdrawal syndrome on health horizons. Frontiers In Genetics 2024, 14: 1292148. PMID: 38264209, PMCID: PMC10805101, DOI: 10.3389/fgene.2023.1292148.Peer-Reviewed Original ResearchAltmetricConceptsNeonatal opioid withdrawal syndromeOpioid withdrawal syndromePlacental tissueWithdrawal syndromeLong-term clinical implicationsPrenatal opioid exposureNOWS treatmentPrenatal opioidsOpioid exposureOpioid effectsOpioid usePharmacologic treatmentCYP genesControl mothersMultiple CYP genesValuable biomarkerClinical implicationsInfantsPersonalized treatmentOpioidsCytochrome P450 enzymesInfinium MethylationEPIC BeadChipTreatmentIllumina Infinium MethylationEPIC BeadChipSyndrome
2023
The Current Status of Medical Student Education on Opioids
Jegede O, Na P, Petrakis I, Muvvala S. The Current Status of Medical Student Education on Opioids. 2023, 121-138. DOI: 10.1093/oxfordhb/9780197618431.013.5.Peer-Reviewed Original ResearchFacilitation and Preferred Models for Delivering Substance Use Disorder Treatment in HIV Clinics: Results From a Multisite Randomized Trial
Muvvala S, Gan G, Morford K, Dziura J, Esserman D, Porter E, Chan P, Cornman D, Reynolds J, Yager J, Fiellin D, Edelman E. Facilitation and Preferred Models for Delivering Substance Use Disorder Treatment in HIV Clinics: Results From a Multisite Randomized Trial. Journal Of Addiction Medicine 2023, 17: e388-e391. PMID: 37934538, PMCID: PMC10726383, DOI: 10.1097/adm.0000000000001192.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsOpioid use disorderAlcohol use disorderTobacco use disorderHIV clinicUse disordersAddiction treatmentSubstance use disorder treatmentUse disorder treatmentMaintenance phaseRandomized trialsStaff preferencesImproved outcomesMultisite Randomized TrialImplementation facilitationDisorder treatmentControl phaseClinicCliniciansTreatment modelTreatmentDisordersSignificant differencesInterventionHigher proportionAddiction treatment modelsPlacental microRNA methylome signatures may serve as biomarkers and therapeutic targets for prenatally opioid-exposed infants with neonatal opioid withdrawal syndrome
Radhakrishna U, Nath S, Uppala L, Veerappa A, Forray A, Muvvala S, Metpally R, Crist R, Berrettini W, Mausi L, Vishweswaraiah S, Bahado-Singh R. Placental microRNA methylome signatures may serve as biomarkers and therapeutic targets for prenatally opioid-exposed infants with neonatal opioid withdrawal syndrome. Frontiers In Genetics 2023, 14: 1215472. PMID: 37434949, PMCID: PMC10332887, DOI: 10.3389/fgene.2023.1215472.Peer-Reviewed Original ResearchCitationsAltmetric
2022
Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics
Edelman EJ, Gan G, Dziura J, Esserman D, Porter E, Becker WC, Chan PA, Cornman DH, Helfrich CD, Reynolds J, Yager JE, Morford KL, Muvvala SB, Fiellin DA. Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics. JAMA Network Open 2022, 5: e2236904. PMID: 36251291, PMCID: PMC9577676, DOI: 10.1001/jamanetworkopen.2022.36904.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTobacco use disorderHIV clinicOpioid use disorderUse disordersAlcohol use disorderAddiction treatmentControl periodImplementation facilitationAdoption of medicationsMulticomponent implementation strategyProvision of MOUDUS HIV clinicsMaintenance periodElectronic health record dataHealth record dataEvaluation periodAdult patientsMean ageClinical trialsMAIN OUTCOMEClinicMOUDPatientsDisordersPatient incentivesIntegrating Ambulatory Addiction Consultation Service Into a Community Mental Health Center
Jegede O, Muvvala S, Cahill J, Wade R, Jordan A. Integrating Ambulatory Addiction Consultation Service Into a Community Mental Health Center. Journal Of Addiction Medicine 2022, 17: 126-128. PMID: 36111994, DOI: 10.1097/adm.0000000000001081.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCommunity mental health centerAddiction consult serviceMental health centersHealth centersConsult serviceConsultation serviceModel of careEvidence-based treatmentsAcute settingAmbulatory settingAddiction treatmentCareAmbulatory systemDrugsAddiction professionalsTreatmentPatientsReplicable modelSettingPatients' perspectives of medications for addiction treatment in HIV clinics: A qualitative study
Morford KL, Muvvala SB, Chan PA, Cornman DH, Doernberg M, Porter E, Virata M, Yager JE, Fiellin DA, Edelman EJ. Patients' perspectives of medications for addiction treatment in HIV clinics: A qualitative study. Journal Of Substance Use And Addiction Treatment 2022, 139: 108767. PMID: 35341613, PMCID: PMC9187601, DOI: 10.1016/j.jsat.2022.108767.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSubstance use disordersHIV clinicAddiction treatmentSubstance useEvidence-based medicationsMedication treatment optionsMedication side effectsHealth Services frameworkFocus groupsHIV cliniciansTreatment optionsMultidisciplinary screeningChronic diseasesPatient educationPatient's perspectivePromoting ActionStudy populationDisorder careSide effectsUse disordersPatient receptivityQualitative studyOverall healthClinicKnowledge deficits
2021
Maternal opioid use disorder: Placental transcriptome analysis for neonatal opioid withdrawal syndrome
Radhakrishna U, Nath SK, Vishweswaraiah S, Uppala LV, Forray A, Muvvala SB, Mishra NK, Southekal S, Guda C, Govindamangalam H, Vargas D, Gardella WG, Crist RC, Berrettini WH, Metpally RP, Bahado-Singh RO. Maternal opioid use disorder: Placental transcriptome analysis for neonatal opioid withdrawal syndrome. Genomics 2021, 113: 3610-3617. PMID: 34352367, DOI: 10.1016/j.ygeno.2021.08.001.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsNeonatal opioid withdrawal syndromeOpioid withdrawal syndromeWithdrawal syndromePrenatal opioid exposureOpioid use disorderPlacentas of infantsPlacental tissue samplesP-valueIngenuity Pathway AnalysisOpioid exposureUse disordersUnexposed controlsFDR p-valueGenes CYP1A1Tissue samplesSyndromePathway analysisCYP1A1NewbornsInfantsEtiologyApoBPlacentaGenesGRIN2AReadiness to Provide Medications for Addiction Treatment in HIV Clinics: A Multisite Mixed-Methods Formative Evaluation
Edelman EJ, Gan G, Dziura J, Esserman D, Morford KL, Porter E, Chan PA, Cornman DH, Oldfield BJ, Yager JE, Muvvala SB, Fiellin DA. Readiness to Provide Medications for Addiction Treatment in HIV Clinics: A Multisite Mixed-Methods Formative Evaluation. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2021, 87: 959-970. PMID: 33675619, PMCID: PMC8192340, DOI: 10.1097/qai.0000000000002666.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHIV clinicTreatment medicationsMixed-methods formative evaluationAddiction treatmentTreatment-eligible patientsSubscale scoresAddiction treatment medicationsAdverse health consequencesHIV careMedication complexityTobacco useMedicationsClinicHealth consequencesSite specialistMultidisciplinary teamworkBehavioral servicesTreatment modelOpioidsLocal championsVariable experienceInconsistent availabilityAddiction treatment modelsFocus groupsTreatmentThe effect of varenicline on smoking and drinking outcomes among Black and White adults with alcohol use disorder and co-occurring cigarette smoking: A secondary analysis of two clinical trials
Haeny AM, Gueorguieva R, Montgomery L, Bold KW, Fucito LM, Wu R, Muvvala SB, Zweben A, O'Malley SS. The effect of varenicline on smoking and drinking outcomes among Black and White adults with alcohol use disorder and co-occurring cigarette smoking: A secondary analysis of two clinical trials. Addictive Behaviors 2021, 122: 106970. PMID: 34216871, PMCID: PMC9426655, DOI: 10.1016/j.addbeh.2021.106970.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsEffects of vareniclineAlcohol use disorderCigarette smokingClinical trialsUse disordersWhite adultsEfficacy of vareniclineNumber of drinksVareniclineSmokingPrimary analysisAlcohol treatmentSecondary analysisAlcohol useTrialsBlack participantsDrinking outcomesLinear mixed modelsAdultsWhite peopleWhite participantsMixed modelingCigarettesDisordersTreatment
Academic Achievements and Community Involvement
honor Stephen Fleck Award
Yale School of Medicine AwardYale School of Medicine, Department of PsychiatryDetails06/20/2024United Stateshonor The Irma Bland Award
National AwardAmerican Psychiatric AssociationDetails01/25/2021United Stateshonor Yale PRA Teaching Award
Yale School of Medicine AwardYale Psychiatry Residents AssociationDetails06/18/2012United Stateshonor Residency Award for Overall Excellence
Other AwardDrexel University College of MedicineDetails06/06/2009United Stateshonor Chief Resident Award for Outstanding Service
Other AwardDrexel University College of MedicineDetails06/06/2009United States
Links & Media
News
- August 15, 2024Source: Journal of Addiction Medicine
The Impact of High-Potency Synthetic Opioids on Pharmacotherapies for Opioid Use Disorder: A Scoping Review
- June 21, 2024
Department of Psychiatry Honors Residents, Fellows, Faculty, Staff at 2024 Annual Commencement Ceremonies
- January 26, 2024
Lewis Receives National Institute on Drug Abuse Mentor-Facilitated Training Award
- June 08, 2023
Faculty Network Spotlight: Yale Global Addictions Network